SAN FRANCISCO, July 29 Medivation, Inc. (Nasdaq: MDVN) today announced that it will host a teleconference and webcast with management to discuss second quarter 2009 financial results and provide a general business update on Wednesday, August 5, 2009, at 4:30 p.m. Eastern Time. A press release for the second quarter ended June 30, 2009 will be released after markets close on August 5, 2009.
Advertisement
Interested parties may call 888-287-5532 from the U.S. or +1-719-325-2124 internationally. Individuals interested in listening to the live call via webcast may do so by visiting http://www.medivation.com. A replay of the webcast will be available on the Company's website for 30 days.
Advertisement
About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. In September 2008, Medivation announced a global agreement with Pfizer Inc to develop and commercialize dimebon (latrepirdine) for the treatment of Alzheimer's and Huntington diseases. With Pfizer, the Company is conducting a broad dimebon clinical development program that includes several Phase 3 trials assessing the efficacy and safety of dimebon taken alone or in combination with other Alzheimer's medications in patients with mild, moderate and severe Alzheimer's disease. Further development of dimebon in patients with Huntington disease is also planned. In addition, a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer is ongoing, and a Phase 3 trial is expected to begin this year. For more information, please visit us at http://www.medivation.com.
SOURCE Medivation, Inc.
